安定した基礎治療を受けている原発性免疫グロブリンA腎症の成人患者におけるメザギタマブの試験

基本情報

NCT ID

NCT05174221

ステータス

完了

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

17

治験依頼者名

Takeda

概要

This study will have two parts. The main aims are to: * check the side effects from mezagitamab. * check for long-term side effects from mezagitamab. Before starting the study, participants will be asked to provide a 24-hour urine sample. A few weeks later, if enrolled they will begin receiving a subcutaneous injection (under the skin) of mezagitamab once a week for 8 weeks then once every 2 weeks for 16 weeks. When treatment has ended, there will be a 24-week follow-up period. Participants who receive benefit from the treatment may continue in the second part of the study where they will be monitored for up to 96 weeks and possibly retreated for another 24 weeks.

対象疾患

介入

依頼者（Sponsor）

実施施設 (4)